First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia - Feldman, EJ; Lancet, JE; Kolitz, JE (J Clin Oncol Off J Am Soc Clin Oncol, 2011)
et al.